JP2018188437A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018188437A5 JP2018188437A5 JP2018089499A JP2018089499A JP2018188437A5 JP 2018188437 A5 JP2018188437 A5 JP 2018188437A5 JP 2018089499 A JP2018089499 A JP 2018089499A JP 2018089499 A JP2018089499 A JP 2018089499A JP 2018188437 A5 JP2018188437 A5 JP 2018188437A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- set forth
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 10
- 239000000872 buffer Substances 0.000 claims 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 5
- 229920000053 polysorbate 80 Polymers 0.000 claims 5
- 229940068968 polysorbate 80 Drugs 0.000 claims 5
- 239000003755 preservative agent Substances 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 101710160107 Outer membrane protein A Proteins 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
- 239000002577 cryoprotective agent Substances 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 239000004033 plastic Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 claims 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101100350628 Arabidopsis thaliana PLL3 gene Proteins 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100024153 Cadherin-15 Human genes 0.000 claims 1
- 102100022529 Cadherin-19 Human genes 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 claims 1
- 101000899410 Homo sapiens Cadherin-19 Proteins 0.000 claims 1
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 102100025096 Mesothelin Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960004926 chlorobutanol Drugs 0.000 claims 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 claims 1
- 150000001860 citric acid derivatives Chemical class 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- HXQVQGWHFRNKMS-UHFFFAOYSA-M ethylmercurithiosalicylic acid Chemical compound CC[Hg]SC1=CC=CC=C1C(O)=O HXQVQGWHFRNKMS-UHFFFAOYSA-M 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229940100630 metacresol Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 229960005323 phenoxyethanol Drugs 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 235000021317 phosphate Nutrition 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 229940044519 poloxamer 188 Drugs 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 229920000098 polyolefin Polymers 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 229940074404 sodium succinate Drugs 0.000 claims 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 1
- HELHAJAZNSDZJO-UHFFFAOYSA-L sodium tartrate Chemical compound [Na+].[Na+].[O-]C(=O)C(O)C(O)C([O-])=O HELHAJAZNSDZJO-UHFFFAOYSA-L 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 150000003890 succinate salts Chemical class 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 150000003892 tartrate salts Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502578P | 2017-05-05 | 2017-05-05 | |
| US62/502,578 | 2017-05-05 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018188437A JP2018188437A (ja) | 2018-11-29 |
| JP2018188437A5 true JP2018188437A5 (enExample) | 2021-04-15 |
| JP7325936B2 JP7325936B2 (ja) | 2023-08-15 |
Family
ID=62555170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018089499A Active JP7325936B2 (ja) | 2017-05-05 | 2018-05-07 | 改善された貯蔵及び投与のための、二重特異性抗体構築物を含む医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11918650B2 (enExample) |
| EP (1) | EP3618864A1 (enExample) |
| JP (1) | JP7325936B2 (enExample) |
| KR (1) | KR102700015B1 (enExample) |
| CN (1) | CN110913904A (enExample) |
| AR (1) | AR111773A1 (enExample) |
| AU (1) | AU2018261951B2 (enExample) |
| BR (1) | BR112019022751A2 (enExample) |
| CA (1) | CA3060856A1 (enExample) |
| CL (1) | CL2019003166A1 (enExample) |
| EA (1) | EA201992613A1 (enExample) |
| IL (1) | IL270239B2 (enExample) |
| MA (1) | MA48763A (enExample) |
| MX (1) | MX2019013142A (enExample) |
| SG (1) | SG11201909547TA (enExample) |
| TW (1) | TWI868050B (enExample) |
| UY (1) | UY37726A (enExample) |
| WO (1) | WO2018204907A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI796283B (zh) * | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| AR107582A1 (es) | 2016-02-03 | 2018-05-16 | Amgen Res Munich Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| UA126657C2 (uk) | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
| JP7314146B2 (ja) | 2017-12-28 | 2023-07-25 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
| PE20210320A1 (es) | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
| US20210355199A1 (en) | 2018-06-28 | 2021-11-18 | University Of Virginia Patent Foundation | Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling |
| LT4324851T (lt) | 2018-07-19 | 2025-10-10 | Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas | |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| WO2020072306A1 (en) * | 2018-10-01 | 2020-04-09 | Amgen Inc. | Methods for reducing aggregation of bispecific antibodies |
| LT4279082T (lt) * | 2019-01-17 | 2026-05-11 | Immunocore Limited | Farmacinės kompozicijos |
| US20220381790A1 (en) | 2019-02-11 | 2022-12-01 | University Of Virginia Patent Foundation | Selection and blockade of fertilization competent male and female gametes |
| WO2020186247A1 (en) | 2019-03-13 | 2020-09-17 | University Of Virginia Patent Foundation | Compositions and methods for promoting islet viability and enhancing insulin secretion |
| AU2020279224B2 (en) | 2019-05-21 | 2024-12-05 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| US20220306741A1 (en) * | 2019-09-10 | 2022-09-29 | Amgen Inc. | Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity |
| US12370126B2 (en) * | 2019-10-18 | 2025-07-29 | Amgen Inc. | Systems and approaches for drug delivery device reconstitution |
| WO2021081321A1 (en) * | 2019-10-24 | 2021-04-29 | Amgen Inc. | Systems and approaches for drug delivery |
| AU2020370372A1 (en) * | 2019-10-25 | 2022-05-12 | Amgen Inc. | Compositions and methods for minimizing protein loss at low protein concentrations |
| WO2021091906A1 (en) * | 2019-11-04 | 2021-05-14 | Amgen Inc. | Methods for treating leukemia |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| US20230151102A1 (en) * | 2020-01-13 | 2023-05-18 | Aptevo Research And Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
| CA3173587A1 (en) | 2020-03-31 | 2021-10-07 | Chugai Seiyaku Kabushiki-Kaisha | Dll3-targeting multispecific antigen-binding molecules and uses thereof |
| AU2021263813A1 (en) | 2020-04-29 | 2022-10-27 | Amgen Inc. | Pharmaceutical formulation |
| IL297081A (en) * | 2020-04-29 | 2022-12-01 | Amgen Inc | Pharmaceutical formulation |
| WO2021228760A1 (en) * | 2020-05-11 | 2021-11-18 | Medimmune Limited | Formulations of anti-il-33 antibodies |
| KR20230008759A (ko) * | 2020-05-11 | 2023-01-16 | 엘커메스 파마 아일랜드 리미티드 | Il-2 융합 폴리펩티드 조성물 및 그의 제조 및 사용 방법 |
| CN111529721B (zh) * | 2020-05-22 | 2021-08-31 | 四川大学 | 一种自聚型纳米诊疗系统及其制备方法和应用 |
| AU2021281356A1 (en) * | 2020-05-29 | 2023-01-19 | Verseau Therapeutics, Inc. | Anti-VSIG4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
| CA3183934A1 (en) * | 2020-05-29 | 2021-12-02 | Amgen Inc. | Antibody formulations and uses thereof |
| WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| US20240092903A1 (en) | 2020-06-12 | 2024-03-21 | Ichnos Sciences SA | Antibody formulation diluent |
| CN116323667A (zh) * | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| EP4200333A1 (en) * | 2020-08-24 | 2023-06-28 | Amgen Inc. | Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine |
| CA3194762A1 (en) * | 2020-09-11 | 2022-03-17 | Amgen Inc. | Materials and methods to reduce protein aggregation |
| WO2022094148A1 (en) | 2020-10-30 | 2022-05-05 | Encodia, Inc. | Conjugation reagents and methods using 1,2-cyclohexanediones |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| CN112244025A (zh) * | 2020-11-27 | 2021-01-22 | 上海创宏生物科技有限公司 | 大分子蛋白和/或核酸用无菌处理剂及其制备方法和应用 |
| AU2022304662A1 (en) * | 2021-06-30 | 2023-11-23 | Amgen Inc. | Method of reconstituting lyophilized formulation |
| WO2023088295A1 (zh) * | 2021-11-17 | 2023-05-25 | 江苏先声药业有限公司 | 一种多特异性抗体及其药物用途 |
| CN116333152A (zh) * | 2021-12-22 | 2023-06-27 | 泰泽惠康生物医药有限责任公司 | 抗cd3×抗cd19双特异性抗体 |
| CN114748618B (zh) * | 2022-04-02 | 2024-07-19 | 重庆智翔金泰生物制药股份有限公司 | 包含针对狂犬病病毒g蛋白的双特异性抗体的药物制剂及其制备方法 |
| CN117088974B (zh) * | 2023-08-14 | 2024-02-13 | 武汉健昊生物科技有限公司 | 一种抗体保存液 |
| US12698512B2 (en) | 2023-11-06 | 2026-08-04 | City Of Hope | Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers |
| WO2025235515A1 (en) | 2024-05-07 | 2025-11-13 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex formulations |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| EP0320015B1 (en) | 1987-12-09 | 1994-07-20 | Omron Tateisi Electronics Co. | Inductive data communicating apparatus |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0575319T3 (da) | 1991-03-11 | 2000-07-10 | Univ Georgia Res Found | Kloning og ekspression af Renilla-luciferase |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| WO1994000569A1 (en) | 1992-06-18 | 1994-01-06 | Genpharm International, Inc. | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2169298A1 (en) | 1993-09-10 | 1995-03-16 | Martin Chalfie | Uses of green fluorescent protein |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| EP0773288A3 (en) | 1995-08-29 | 1997-07-09 | Kirin Brewery | Chimera animal and its method of manufacture |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
| US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
| US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| ATE290205T1 (de) | 1996-12-12 | 2005-03-15 | Prolume Ltd | Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| AU765703B2 (en) | 1998-03-27 | 2003-09-25 | Bruce J. Bryan | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| ES2207278T3 (es) | 1998-07-28 | 2004-05-16 | Micromet Ag | Heterominicuerpos. |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| ES2645563T3 (es) | 2001-11-30 | 2017-12-05 | Amgen Fremont Inc. | Animales transgénicos que portan genes de cadena ligera de Ig humana |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| EP2225275A4 (en) * | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| JP5798036B2 (ja) * | 2008-11-07 | 2015-10-21 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 小児急性リンパ芽球性白血病の新規治療 |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| EP2658739B1 (de) | 2010-12-30 | 2017-02-22 | Johnson Controls Metals and Mechanisms GmbH & Co. KG | Längsverstellvorrichtung eines kraftfahrzeugsitzes mit zwei schienenpaaren |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| WO2014151910A1 (en) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| WO2015048272A1 (en) | 2013-09-25 | 2015-04-02 | Amgen Inc. | V-c-fc-v-c antibody |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| US10105142B2 (en) | 2014-09-18 | 2018-10-23 | Ethicon Llc | Surgical stapler with plurality of cutting elements |
| JOP20170017B1 (ar) * | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
-
2018
- 2018-05-07 MA MA048763A patent/MA48763A/fr unknown
- 2018-05-07 BR BR112019022751A patent/BR112019022751A2/pt unknown
- 2018-05-07 US US15/972,489 patent/US11918650B2/en active Active
- 2018-05-07 KR KR1020197035356A patent/KR102700015B1/ko active Active
- 2018-05-07 UY UY0001037726A patent/UY37726A/es active IP Right Grant
- 2018-05-07 EP EP18729833.6A patent/EP3618864A1/en active Pending
- 2018-05-07 WO PCT/US2018/031347 patent/WO2018204907A1/en not_active Ceased
- 2018-05-07 CA CA3060856A patent/CA3060856A1/en active Pending
- 2018-05-07 JP JP2018089499A patent/JP7325936B2/ja active Active
- 2018-05-07 AR ARP180101193A patent/AR111773A1/es not_active Application Discontinuation
- 2018-05-07 CN CN201880029340.3A patent/CN110913904A/zh active Pending
- 2018-05-07 SG SG11201909547T patent/SG11201909547TA/en unknown
- 2018-05-07 EA EA201992613A patent/EA201992613A1/ru unknown
- 2018-05-07 MX MX2019013142A patent/MX2019013142A/es unknown
- 2018-05-07 AU AU2018261951A patent/AU2018261951B2/en active Active
- 2018-05-07 TW TW107115491A patent/TWI868050B/zh active
- 2018-05-07 IL IL270239A patent/IL270239B2/en unknown
-
2019
- 2019-11-04 CL CL2019003166A patent/CL2019003166A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021504372A5 (enExample) | ||
| KR102372245B1 (ko) | 항체-약물 접합체 동결건조 제제 | |
| KR102843708B1 (ko) | 이중특이적 항체 작제물을 포함하는 약제학적 조성물 | |
| KR102359181B1 (ko) | 항-ｒｓｖ 모노클로날 항체 제제 | |
| US20100158925A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
| US20200262922A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| JP2016534052A5 (enExample) | ||
| JP2020509031A5 (enExample) | ||
| EA031436B1 (ru) | Водная фармацевтическая композиция, содержащий ее предварительно заполненный шприц и применение композиции в лечении аутоиммунных заболеваний | |
| FI3576788T3 (fi) | Matalan ph-arvon omaava farmaseuttinen koostumus, joka käsittää t-soluihin sitoutuvia vasta-ainekonstrukteja | |
| JP2017512814A (ja) | 抗ｃｄ１９抗体および抗体−薬物結合体のための安定な製剤 | |
| TW201028167A (en) | Pharmaceutical composition | |
| TW200417377A (en) | Stable pH optimized formulation of a modified antibody | |
| JP2018519303A (ja) | 抗体デュオカルマイシン薬物複合体を含む組成物 | |
| CA3072600A1 (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| TW202220702A (zh) | 一種含抗體藥物偶聯物的醫藥組成物及其用途 | |
| US20220378908A1 (en) | Compositions and methods for minimizing protein loss at low protein concentrations | |
| WO2023143347A1 (zh) | 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途 | |
| TW201902518A (zh) | 一種含c-Met抗體藥物偶聯物的醫藥組成物及其用途 | |
| CN115279405B (zh) | 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途 | |
| WO2023056473A1 (en) | Anti-human astrovirus antibodies and related compositions and methods | |
| WO2026067821A1 (zh) | 一种抗pd-1抗体制剂及其制备方法和用途 | |
| WO2025056005A1 (zh) | 抗tim-3抗体的药物组合物及用途 | |
| WO2026092502A1 (zh) | 一种包含抗tf抗体药物偶联物的药物组合物 | |
| JP2024513473A (ja) | Ｄｐｅｐ－１結合物質および使用の方法 |